Elizabeth John, PhD

Head of CMC

Dr. John has over 25 years of hands-on industry experience in the development of analytical methods, formulations, and processes for drugs and biologics.  She is highly knowledgeable and experienced in drug development, providing a detailed understanding of the product development process from discovery through the various clinical phases. She has led the CMC development, quality control, and IND-filing of numerous therapeutic proteins, peptides, and small molecules.

Since 2010, she has been working as CMC/Regulatory consultant. Dr. John was VP of CMC Development at EnzymeRx (acquired by 3SBio), VP of Pharmaceutical Development / Regulatory Affairs at Proacta, Inc, Director of Pharmaceutical Development / Regulatory Affairs at Celmed Biosciences, and managerial roles at NewBiotics and NeoRx Corp. She holds a Master’s degree in chemistry from Indian Institute of Technology, Doctorate in Chemistry from Rutgers University, and was a post-doctoral fellow at Purdue University in Medicinal Chemistry in the College of Pharmacy.